Skip to content

Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function

The NATURE Study (Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07408713
Acronym
NATURE
Enrollment
100
Registered
2026-02-13
Start date
2026-02-15
Completion date
2031-12-31
Last updated
2026-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HSCT, Late Effect, Neurocognitive Dysfunction, Pediatric Cancer, Pediatric Patients, Physical Capacity, Physical Function, Toxicity

Brief summary

Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving treatment for children with relapsed or resistant leukemia and other life-threatening hematological and hereditary disorders. In Denmark, around 25 children undergo allogeneic HSCT every year, of these approximately 85-90% survive into adulthood. The goal of this observational study is to learn about neurocognitive outcomes in children undergoing (HSCT) and to understand which clinical, physical, and environmental factors may affect neurocognitive development during the first year after transplant. The main questions it aims to answer are: How does neurocognitive function change from before HSCT to one year after transplantation in pediatric patients? Which clinical, physical, and environmental factors are linked to better or worse neurocognitive outcomes? Participants will: Complete neurocognitive tests before HSCT and at 1-year follow-up, covering intelligence, memory, attention, executive function, processing speed, and motor skills. Undergo physical tests before HSCT, at hospital discharge, at 6-months follow-up, and at 1-year follow-up, including muscle strength, mobility, endurance, balance, and cardiopulmonary fitness (only at 1-year follow-up). Wear activity trackers to measure physical activity and sedentary time during hospitalization at 6 months and 1-year post-HSCT. Complete questionnaires about sleep, pain, quality of life, fatigue, family background, and exposure to outdoor and green spaces. Have medical records reviewed for treatment-related side effects, immune recovery, inflammation, and pain management. This study will help understand how neurocognitive function develops after HSCT in children and which factors (clinical, physical, or environmental) may support better recovery and well-being.

Interventions

None listed

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER
Jascha Fonden
CollaboratorOTHER
The Dagmar Marshall Foundation
CollaboratorOTHER
Gangsted Foundation
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Recipient of allogeneic HSCT in the study period 2. HSCT at the pediatric ward 3. Age \<18 years at referral to HSCT 4. Signed informed consent

Exclusion criteria

1\) Inability of legal guardian to speak and understand Danish

Design outcomes

Primary

MeasureTime frameDescription
Performance on clinical neurocognitive testsT0: Within 30 days prior to HSCT T3: 1 year post HSCTScores on the clinical neurocognitive tests (Bayley-III: Bayley Scales of Infant and Toddler Development - Third Edition, WPPSY-IV: Wechsler Preschool and Primary Scale of Intelligence 2.6-7.7 years of age, WISC-V: Wechler Intelligence Scale for Children Fifth edition for participants 7-15.9 years of age, WAIS-IV: Wechler Adult Intelligence Scale Fourth edition for participants 16 years of age or older). Tested domains: Non-verbal reasoning, verbal reasoning, Working memory, Processing Speed Scaled scores range from 0-19, higher = better performance.
Performance on clinical neurocognitive tests - Excecutive functioningT0: Within 30 days prior to HSCT T3: 1 year post HSCTExcecutive functioning will be tested using D-KEFS (Delis-Kaplan Executive Function System) for all participants \>8 y of age.
Performance on clinical neurocognitive tests - Sustained attentionT0: Within 30 days prior to HSCT T3: 1 year post HSCTSustained attention will be tested using CPT-3 (Conners Continuous Performance Test, 3rd Edition) for for all participants \>8 y of age
Performance on clinical neurocognitive tests - Visuomotor functionsT0: Within 30 days prior to HSCT T3: 1 year post HSCTVisuomotor functions will be tested using Beery VMI (Beery-Buktenica Developmental Test of Visual-Motor Integration)
Performance on clinical neurocognitive tests - Verbal learningT0: Within 30 days prior to HSCT T3: 1 year post HSCTVerbal learning will be tested using TOMAL-2 \>6 y of age

Secondary

MeasureTime frameDescription
Isometric Muscle StrengthT0: Within 30 days prior to HSCT T1: During HSCT (at discharge, or day +42 at latest) T2: 6 months post HSCT T3: 1 year post HSCTIsometric knee strength will be measured with a handheld dynamometer (CITEC handheld dynamometer, type 3002, CIT Technics, Haren, Netherlands). Maximum isometric contraction will be evaluated using the "break technique" (Beenakker et al, 2001). The highest value out of three repetitions will be counted as the maximum strength and kept for analysis. The handheld dynamometry method has shown high validity (r = 0.74 and r = 0.98) and moderate intertester reliability (r = 0.42 to r = 0.73) in healthy and chronically ill children and adolescents (Brussock CM et al. (1992)), (Stuberg WA et al (1988)) and is considered a reliable and valid instrument for muscle strength assessment in a clinical setting compared to the gold standard isokinetic dynamometry (Stark T et al (2011)).
Handgrip strengthT0: Within 30 days prior to HSCT T1: During HSCT (at discharge, or day +42 at latest) T2: 6 months post HSCT T3: 1 year post HSCTHandgrip strength will be measured using a hand-held dynamometer. Participants are placed in a seated position with the elbow flexed at 90°, with three attempts performed for each hand. During testing, the participant will be encouraged to exhibit the best possible force, and the best measure in the strongest hand will be used as the test score. Handgrip strength is also used as a surrogate measure for upper-body physical function (Bohannon RW et al (2001)), Adam C et al (1988))
Muscle performance: Sit-to-stand 30 sec.T0: Within 30 days prior to HSCT T1: During HSCT (at discharge, or day +42 at latest) T2: 6 months post HSCT T3: 1 year post HSCTSit-to-Stand 30 sec: The participant sits on a chair allowing the participant to flex the legs at a 90 degree angle. The participant is instructed to stand up straight, and return to sitting, as many times as possible in 30 sec. The arms should be crossed in front of the body or hanging by the side. Number of repititions is the outcome.
Muscle performance: Sit-to-stand 60 sec.T0: Within 30 days prior to HSCT T1: During HSCT (at discharge, or day +42 at latest) T2: 6 months post HSCT T3: 1 year post HSCTSit-to-Stand 60 sec: The participant sits on a chair allowing the participant to flex the legs at a 90 degree angle. The participant is instructed to stand up straight, and return to sitting, as many times as possible in 60 sec. The arms should be crossed in front of the body or hanging by the side. Number of repititions is the outcome.
Muscle performance: Timed-up-and-goT0: Within 30 days prior to HSCT T1: During HSCT (at discharge, or day +42 at latest) T2: 6 months post HSCT T3: 1 year post HSCTParticipants will sit on a chair with both feet flat on the ground. Subsequently, participants will be instructed to stand up, walk 3 meters, turn around, walk back, and sit down as fast as possible. Each participant will perform the test three consecutive times and the fastest test will be used for the analyses. The timed-up-and-go test depends on lower body muscular strength and balance and reflects a person's ability to move in an everyday setting.
Sensory Interaction in BalanceT0: Within 30 days prior to HSCT T1: During HSCT (at discharge, or day +42 at latest) T2: 6 months post HSCT T3: 1 year post HSCTThis four-condition test is designed to assess how well an individual is using sensory inputs to maintain balance, when one or more sensory systems are compromised. In condition one, all sensory systems (i.e., vision, somatosensory, and vestibular) are available for maintaining balance. In condition two, vision has been removed, and the participant must rely on the somatosensory and vestibular systems to balance. In condition three, the somatosensory system has been compromised, and the participant must use vision and the vestibular system to balance. In condition four, vision has been removed, and the somatosensory system has been compromised. Each trial is timed using a stopwatch. The trial is over when (a) the participant opens his/her eyes in an eyes closed condition, (b) raises arms from sides, (c) loses balance and requires manual assistance to prevent a fall or (d) maintains balance for 30 seconds.
Gross motor skills <5 years of ageT0: Within 30 days prior to HSCT T1: During HSCT (at discharge, or day +42 at latest) T2: 6 months post HSCT T3: 1 year post HSCTThe pre-school children will be evaluated with the Peabody Developmental Motor Scales, Second Edition (PDMS-2) Darrah J, et al (2007). The PDMS-2 is a validated instrument to assess fine and gross motor skills in children from birth to 5 years of age (0-71 months).
Cardiorespiratory fitnessT3: 1 year post HSCTperformed on an electrical-break ergometer bicycle (Lode Corival Pediatric or Monark Ergomedic 839 E) using a modified Godfrey protocol. The participant will be instructed to keep a steady pace (70-80 rpm), while the workload increases gradually with 10-25 watts pr. minute until exhaustion. Oxygen uptake (VO2), heart rate (HR), minute ventilation (VE), respiratory exchange ratio (RER), breathing frequency (BF), and tidal volume (TV) will be measured continuously during the test using a transportable a portable Cortex Metamax 3B wireless spirometry system (Cortex, Leipzig, Germany). The participant will breathe into a Hans Rudolph Valve (2-wat NRBV, Hans Rudolph Inc., Kansas City, MO, USA). Heart rate and oxygen saturation will be measured during the test. Furthermore, two objective criteria need to be fulfilled before the test is valid: 1) heart rate \>85% of estimated maximal heart rate 2) respiratory exchange ratio (RER)\>1.1. The primary outcome will be the peak oxygen uptake(V02max)
Physical Activity and Sedentary TimeT1: During HSCTThese parameters will be assessed by an accelerometer. The accelerometers (ActiGraph™ model GT3X+, ActiGraph LLC, Pensacola FL, USA) measure accelerations of ±6 G. The sample rate will be set to measure raw signals at 100 Hz, translated into metabolic energy equivalents of light, moderate, and vigorous physical activity and sedentary time. The validity of the Actigraph accelerometer is good, with correlations of 0.65 between accelerometer assessed metabolic energy equivalents and indirect calorimetry. We will investigate whether international guidelines for physical activity are met (Troiano RP et al, 2008) according to established cut-off levels . Measurements during hospitalization will cover the waking hours of as many days as possible.
Pain and morphine usage:T1: During HSCTThe cumulative dose of morphine-equivalents during the transplantation will be retrieved from medical records.
MucositisT1: During HSCTThe level of mucositis will be graded daily during the period of neutropenia by the nursing staff, and subsequently retrieved from patient files. The CTCAE classification is used: Grade 1: asymptomatic or mild mucositis; intervention not indicated. Grade 2: moderate pain or ulcer that does not interfere with oral intake; modified diet indicated. Grade 3: severe pain; interfering with oral intake. Grade 4: life-threatening consequences; urgent intervention indicated
Level of inflammation and immunityT1: During HSCT• Inflammatory parameters including C-reactive protein levels will be retreived from patients' files
Inclusion of Nature in SelfT0: Within 30 days prior to HSCT T3: 1 year post HSCTThe Inclusion of Nature in Self (INS) Scale is a validated single-item visual measure of children's connectedness to nature and is available in a Danish translation. Nature connectedness has been linked to better psychological well-being, lower distress, and improved emotional regulation, supporting its relevance as a protective factor. The INS can be used both as a baseline measure and to assess changes over time. Its simple visual format makes it particularly suitable for children. Children aged 8-18 years will complete the survey themselves, while parents/caregivers will respond for children aged 0-7 years
Nature Connectedness Index (NCI)T0: Within 30 days prior to HSCT T3: 1 year post HSCTNature Connectedness Index (NCI) is a brief, validated 6-item questionnaire designed to assess an individual's emotional and cognitive connection to the natural environment. The items capture aspects such as enjoyment of nature, feeling part of nature, and interest in engaging with the natural world. Responses are rated on a Likert scale, with higher scores indicating greater connectedness to nature. In this study, the NCI will be administered as a self-report for children and adolescents aged 8-18 years. For younger children aged 0-7 years, the questionnaire will be completed by a parent or primary caregiver on behalf of the child, based on their observations of the child's behaviors and attitudes toward nature.
Experiences with and perceptions of natureT0: Within 30 days prior to HSCT T3: 1 year post HSCTThe Children's People and Nature Survey (C-PANS) is a brief 6-item questionnaire designed to capture children's experiences with nature, including outdoor time, enjoyment, and environmental concern. Although formal validation is still underway, recent Danish reference data from a nationally representative sample provide a useful benchmark, making C-PANS relevant in a Danish context. In this study, children aged 8-18 years will complete the survey themselves, while parents/caregivers will respond for children aged 0-7 years. Two items overlap between the NCI and C-PANS; these will be asked only once.
Pediatric Quality of Life Inventory (PedsQL™) 4.0 Generic Core Scales - Child and Parent ReportT0: Within 30 days prior to HSCT T3: 1 year post HSCTThe PedsQL 4.0 Generic Core Scales assess health-related quality of life in children across four domains: physical functioning, emotional functioning, social functioning, and school functioning. The instrument uses a 5-point Likert scale (0 = never a problem; 4 = almost always a problem) - lower score meaning better outcome.
Pediatric Quality of Life Inventory (PedsQL™) Multidimensional Fatigue Scale - Child and Parent ReportT0: Within 30 days prior to HSCT T3: 1 year post HSCTThe PedsQL Multidimensional Fatigue Scale assesses fatigue in children in three domains: general fatigue, sleep/rest fatigue, and cognitive fatigue. It uses the same 5-point Likert scale (0 = never a problem; 4 = almost always a problem) - lower score meaning better outcome.
Cognitive functioning measured by the PROMIS® Cognitive Function Short Form 8a - Self-ReportT0: Within 30 days prior to HSCT T3: 1 year post HSCTThe PROMIS® Cognitive Function Short Form 8a is an 8-item self-report questionnaire assessing perceived cognitive functioning in the past 7 days. It evaluates aspects such as memory, mental clarity, and concentration. Each item is scored on a 5-point Likert scale ranging from 1 ("very often") to 5 ("never") - higher scores indicate better subjective cognitive functioning.
Physical activity measured by the PROMIS® Physical Activity Short Form 4a - Self-ReportT0: Within 30 days prior to HSCT T3: 1 year post HSCTThe PROMIS® Physical Activity Short Form 4a is a 4-item self-report questionnaire that assesses the frequency and intensity of physical activity during the past 7 days. Items are rated on a 5-point Likert scale, with higher scores indicating higher levels of physical activity
Patient and parental distressT1: During HSCTPatient and parental distress will be assessed using the validated Distress Thermometer, which has previously been applied in pediatric HSCT and other cancer populations. The instrument consists of a visual analogue "thermometer" indicating the level of distress from 0 to 10, and an accompanying problem checklist, allowing respondents to identify relevant sources of distress. The Distress Thermometer will be administered to patients aged ≥10 years and to at least one parent per patient, specifically the parent primarily present during the patient's hospitalization. Assessments in both the patients and parents will be conducted on the day of hospital admission, five days prior to HSCT (day -5), on the day of transplantation (day 0), and subsequently on day +7, +14, +21, +28, +35, +42, +50, and +60, as well as on the day of discharge. If discharge occurs before the planned assessment schedule, the final assessment will be conducted on the day of discharge.

Countries

Denmark

Contacts

CONTACTHilde H Uhlving, MD, PhD
hilde.hylland.uhlving@regionh.dk+45 35451356
CONTACTKristian B Jeppesen
kristian.bohn.jeppesen@regionh.dk+45 24604838

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026